Reviewer’s report

Title: CHCHD2 is a potential prognostic factor for NSCLC and is associated with HIF-1a expression

Version: 2 Date: 01 Jan 2020

Reviewer: Kangsheng Tu

Reviewer's report:

Previous study has reported that CHCHD2 is coamplified with EGFR in NSCLC and regulates mitochondrial function and cell migration. Here, authors tried to demonstrate that high CHCHD2 expression was correlated with poor prognostic features and reduced survival. Moreover, the expression of CHCHD2 was positively correlated with HIF-1a in NSCLC tissues. This provides a new insight into the clinical significance of CHCHD2 in NSCLC. However, several major issues require to be addressed.

1. Representative IHC pictures for different staining grades should be provided.

2. The expression difference of CHCHD2 between NSCLC and normal tissues, as well as its prognostic value should be further confirmed in TCGA database.

3. HIF-1a and HIF-2a are two main effectors of hypoxia. Thus, it is necessary to analyze the correlation between CHCHD2 and HIF-2a.

4. Does the combination of CHCHD2 and HIF-1a predict the poorest survival of patients?

Are the methods appropriate and well described?
If not, please specify what is required in your comments to the authors.

Yes

Does the work include the necessary controls?
If not, please specify which controls are required in your comments to the authors.

Yes

Are the conclusions drawn adequately supported by the data shown?
If not, please explain in your comments to the authors.

Yes
Are you able to assess any statistics in the manuscript or would you recommend an additional statistical review?
If an additional statistical review is recommended, please specify what aspects require further assessment in your comments to the editors.

I am able to assess the statistics

**Quality of written English**
Please indicate the quality of language in the manuscript:

Needs some language corrections before being published

**Declaration of competing interests**
Please complete a declaration of competing interests, considering the following questions:

1. Have you in the past five years received reimbursements, fees, funding, or salary from an organisation that may in any way gain or lose financially from the publication of this manuscript, either now or in the future?

2. Do you hold any stocks or shares in an organisation that may in any way gain or lose financially from the publication of this manuscript, either now or in the future?

3. Do you hold or are you currently applying for any patents relating to the content of the manuscript?

4. Have you received reimbursements, fees, funding, or salary from an organization that holds or has applied for patents relating to the content of the manuscript?

5. Do you have any other financial competing interests?

6. Do you have any non-financial competing interests in relation to this paper?

If you can answer no to all of the above, write 'I declare that I have no competing interests' below. If your reply is yes to any, please give details below.

I declare that I have no competing interests

I agree to the open peer review policy of the journal. I understand that my name will be included on my report to the authors and, if the manuscript is accepted for publication, my named report including any attachments I upload will be posted on the website along with the authors' responses. I agree for my report to be made available under an Open Access Creative Commons CC-BY license ([http://creativecommons.org/licenses/by/4.0/](http://creativecommons.org/licenses/by/4.0/)). I understand that any comments which I do not wish to be included in my named report can be included as confidential comments to the editors, which will not be published.

I agree to the open peer review policy of the journal